The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Brand Loyalty, Entry, and Price Competition in Pharmaceuticals after the 1984 Drug Act
Open accessAbstract
IN 1984, Congress enacted a new law that greatly affected the economics\nof the pharmaceutical industry in the United States. It has been characterized\nas the most important legislation affecting competition in the pharmaceutical\nindustry since the 1962 Kefauver-Harris Amendments to the\nFood and Drug Act. This 1984 law, known as the Drug Price Competition\nand Patent Term Restoration Act (hereinafter the 1984 Act), facilitated\nthe entry of generic drug products after patent expiration while it also\nrestored part of the patent life lost during the premarket regulatory process\nfor new introductions.1\nMarket entry by generics was relatively limited prior to 1984 because\nof costly Food and Drug Administration (FDA) requirements that had to\nbe met by the imitative products. That is, generic drugs often would have\nto duplicate many of the pioneer's tests to gain market approval after\npatent expiration. As a result of the 1984 law, generic products need only\ndemonstrate bioequivalence to the pioneer's brand, and generic entry has\nincreased significantly. This has provided a body of very interesting data\nto analyze the pattern of entry and the pricing strategies followed by the\nentrants and incumbents.\nIn this article, we make use of data covering the sales and prices of\nthe pioneer and generic products for eighteen drug products, generally\nover the time period 1984-88.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Industrial Market Structure and Economic Performance.
Mann, H. M., & Scherer, F. M. (1971) · The Journal of Finance · doi:10.2307/2325977 · Cited by 6,267
Product differentiation advantages of pioneering brands
Schmalensee, R. (1980) · American Economic Review · Cited by 723
A New Look at the Returns and Risks to Pharmaceutical R&D
Grabowski, H., & Vernon, J. (1990) · Management Science · doi:10.1287/mnsc.36.7.804 · Cited by 286
Self-citationPersuasion or Information? Promotion and the Shares of Brand Name and Generic Pharmaceuticals
Hurwitz, M. A., & Caves, R. E. (1988) · The Journal of Law and Economics · doi:10.1086/467158 · Cited by 254
Cited by
Roberts, P. W. (1999) · Strategic Management Journal · doi:10.1002/(sici)1097-0266(199907)20:7<655::aid-smj44>3.0.co;2-p · Cited by 704
The economic analysis of advertising
Bagwell, K. W. (2005) · RePEc: Research Papers in Economics · doi:10.7916/d8qz2p6x · Cited by 648
Chapter 28 The Economic Analysis of Advertising
Bagwell, K. (2007) · Handbook of Industrial Organization · doi:10.1016/s1573-448x(06)03028-7 · Cited by 545
Qian, Y. (2007) · Review of Economics and Statistics · doi:10.1162/rest.89.3.436 · Cited by 479
Evolution of R&D Capabilities: The Role of Knowledge Networks Within a Firm
Nerkar, A., & Paruchuri, S. (2005) · Management Science · doi:10.1287/mnsc.1040.0354 · Cited by 466
Cunningham, C., Ederer, F., & Ma, S. (2021) · Journal of Political Economy · doi:10.1086/712506 · Cited by 452
Uncertainty and Learning in Pharmaceutical Demand
Crawford, G. S., & Shum, M. (2005) · Econometrica · doi:10.1111/j.1468-0262.2005.00612.x · Cited by 433
Generic Entry and the Pricing of Pharmaceuticals
Frank, R. G., & Salkever, D. S. (1997) · Journal of Economics & Management Strategy · doi:10.1111/j.1430-9134.1997.00075.x · Cited by 374
Innovation and corporate growth in the evolution of the drug industry
Bottazzi, G., Dosi, G., Lippi, M., Pammolli, F., & Riccaboni, M. (2001) · International Journal of Industrial Organization · doi:10.1016/s0167-7187(01)00068-6 · Cited by 368
Paruchuri, S., Nerkar, A., & Hambrick, D. C. (2006) · Organization Science · doi:10.1287/orsc.1060.0207 · Cited by 347
Khanna, R., Guler, I., & Nerkar, A. A. (2015) · SSRN Electronic Journal · doi:10.2139/ssrn.2629419 · Cited by 313
Generic Drug Industry Dynamics
Reiffen, D., & Ward, M. R. (2005) · Review of Economics and Statistics · doi:10.1162/0034653053327694 · Cited by 312
Pharmaceutical Price Controls and Entry Strategies
Kyle, M. K. (2007) · Review of Economics and Statistics · doi:10.1162/rest.89.1.88 · Cited by 297
Cross-national price differences for pharmaceuticals: how large, and why?
Danzon, P. M., & Chao, L.-W. (2000) · Journal of Health Economics · doi:10.1016/s0167-6296(99)00039-9 · Cited by 285
Platform Siphoning: Ad-Avoidance and Media Content
Anderson, S. P., & Gans, J. S. (2011) · American Economic Journal: Microeconomics · doi:10.1257/mic.3.4.1 · Cited by 87
Product concentration and usage: Behavioral effects in the glyphosate market
Perry, E. D., Hennessy, D. A., & Moschini, G. (2019) · Journal of Economic Behavior & Organization · doi:10.1016/j.jebo.2018.12.027 · Cited by 24
Metadata
- Authors
- Grabowski, H. G., & Vernon, J. M.
- Venue
- The Journal of Law and Economics
- Publisher
- University of Chicago Press
- Published
- 1992-10
- Volume
- 35
- Issue
- 2
- Pages
- 331-350
- ISSN
- 0022-2186 (ISSN-L)
- 1537-5285
- OpenAlex
- W2007927184
- Cited by
- 574
- References
- 4
- FWCI
- 9.30
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.